% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

sauve9 16 posts  |  Last Activity: May 19, 2016 4:31 PM Member since: Mar 12, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by jackdiane759 Feb 2, 2016 12:33 PM
    sauve9 sauve9 May 19, 2016 4:31 PM Flag

    Cindy McGee now at Auris Medical AG

  • Henley Business School
    University of Reading

    Supported and sponsored by the Thames Valley Berkshire Business Growth hub, the University of Reading's Henley Centre for Entrepreneurship, and Oxford Academic Health Sciences Network hosted 'From research to commercialisation - Health & Food' SME Forum at Henley Business School on Wednesday 17 February 2016.

    The presentations were opened with Dominic Bevan, Executive VP and Chief Scientific Officer at Arena Pharma, a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors to address a wide range of medical needs.

    Dr Behan. highlighted the value of SME collaboration with academia and picked out the specific collaboration with Prof John Gibbins at the University of Reading that enabled Arena to build it's understanding of the molecular mechanisms that regulate the function of platelets in haemostasis and thrombosis and development of new strategies for the prevention of thrombosis.

    Dr. Behan described two new 'best in class' molecules in development - an oral prostacyclin receptor agonist for vascular disease and a serotonin 5HT2A receptor inverse agonist for thrombotic diseases - that have resulted from the collaboration with Prof. Gibbins.

    The verdict from Dr. Behan was collaboration with the University of Reading was 'invaluable and pivotal' in driving progress in R&D.
    Dominic Behan studied at Leeds (BSc Biochemistry) and Reading (PhD Biochemistry) and then began his industrial career at Neurocrine Biosciences directing several drug discovery programmes. In 1997, he co-founded Arena Pharmaceuticals.
    Dominic is on the PharmaVOICE 100 list of most-inspiring people in the life sciences industry.
    Dominic was awarded a higher doctorate (DSc) by the University of Reading, where he is Visiting Professor, and is exploring collaborations with the University’s Institute for Cardiovascular and Metabolic Research in the areas of
    thrombosis and cardiovascular disease.

    Sentiment: Strong Buy

  • Reply to

    It's wonderful

    by sauve9 May 11, 2016 12:40 PM
    sauve9 sauve9 May 11, 2016 12:49 PM Flag

    The Psychomachia (Battle of spirits or soul war) by the Late Antique Latin poet Prudentius, from the early fifth century

    Sentiment: Strong Buy

  • sauve9 by sauve9 May 11, 2016 12:40 PM Flag

    Feeling really good about my Arena investment.
    I see a slow two-year grind up to about $12.00
    300% annualized is pretty good.
    Patience is a virtue.
    Anger attacks Patience, but cannot defeat or even injure her; driven mad with frustration, Anger ultimately kills herself instead.

    Sentiment: Strong Buy

  • After several years at J&J, Astra Merck, and Amgen, I co-founded Kythera Biopharmaceuticals in 2005. Starting a biotechnology company from scratch has been a difficult and deeply rewarding experience, both from a value-creation and a knowledge-expanding point-of-view.
    I am a high-energy, passionate person. I lead by creating a common purpose, and then give the talented people around me lots of room to get the job done.
    I look to surround myself with people who have a global perspective (understanding or having worked in global markets is a good indicator of adaptability), and can change strategies, tactics, and approaches as the business situation dictates. A significant element of this is the ablity to run lean, highly virtual teams. There are far too many fixed costs and legacy “habits” in pharma and biotech today.
    Pharma has been relatively insulated compared to other businesses that have faced major structural changes including the full effect of globalization and regulatatory changes. There are lessons to be learned from leaders in other industries that have undergone significant structural changes, and have led their companies into a strong long term position.
    We need to stop thinking of globalization as something that is happening to us (e.g. the rise of China and India), or something to be addressed. It’s the state of the world—if you can’t assemble a team that can effectively immerse themselves in a global perspective, even when making domestic decisions, you may have already lost the game

    Sentiment: Buy

  • sauve9 sauve9 May 3, 2016 3:57 PM Flag

    No I am not

  • Reply to

    Sensor readings indicate

    by sauve9 Mar 24, 2016 11:20 AM
    sauve9 sauve9 Apr 30, 2016 1:06 PM Flag

    I guess we fell back.

  • sauve9 sauve9 Apr 29, 2016 8:44 PM Flag

    I think it will go down a buck or 2 in the first 2 hours and then move up and close $4 higher at $37-ish.

    Sentiment: Strong Buy

  • Reply to

    Axovant article, no mention of ARNA

    by bioimmunomabman Apr 29, 2016 9:02 AM
    sauve9 sauve9 Apr 29, 2016 12:24 PM Flag

    3 thumbs down in 3 minutes = Mon--Key
    Pretty weak mon-key, used to do 20.

  • Reply to

    Axovant article, no mention of ARNA

    by bioimmunomabman Apr 29, 2016 9:02 AM
    sauve9 sauve9 Apr 29, 2016 12:17 PM Flag

    Arena is previewing a movie entitled "Death of the Short-Sellers" which includes free popcorn and the setting of the drapes a-fire.

    Sentiment: Buy

  • sauve9 sauve9 Apr 25, 2016 10:24 PM Flag

    Volume is to shorts what breathing is to life.

    Sentiment: Buy

    on Molecular and Cellular Biology
    New Therapeutics for Diabetes and Obesity (G1)

    April 17-20, 2016 • Estancia La Jolla Hotel & Spa • La Jolla, California, USA

    Scientific Organizers: Richard D. DiMarchi, Matthias H. Tschöp and Nancy A. Thornberry

    Sponsored by Arena Pharmaceuticals, Inc., Janssen R&D: Pharmaceutical Companies of Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S and Regeneron Pharmaceuticals, Inc.

    Meeting is full. Call for details or if you wish to be placed on a waitlist for the meeting.

    Current State of Therapy in Treatment of Obesity
    Steven R. Smith, Florida Hospital, USA
    Identification of Breakthrough Therapies for the Treatment of Diabetes and Obesity: Challenges and Opportunities

    Thue W. Schwartz, University of Copenhagen, Denmark
    Metabolite versus Hormone Receptors - Playing on the Full Enteroendocrine and Pancreatic Orchestra versus Single Instruments

  • Reply to

    Sensor readings indicate

    by sauve9 Mar 24, 2016 11:20 AM
    sauve9 sauve9 Mar 24, 2016 12:11 PM Flag

    We need to hit $2 soon or we fall back

  • "Sensor readings indicate a relative strength of 62 on planet Arena" Spock informed Captain Kirk, "History data banks suggest a pullback shortly after the 63 to 73 range, however, with a warp $2 we can evade the tractor beam"

    "...and if we don't?" asked Kirk.

    "It is a virtual certainty Captain, that 10,000 Areniacs will die"
    [[#####cue music that sounds like holy cow this is serious]]

    "Captain to engine room, Scotty"
    "Yes Captain"
    "We need warp $2 now Scotty"
    "But we are running $1.87 now Captain and she's topping out, the engines cannot take it, and besides Captain, there is a large bid at $1.92!"
    "Drop the phaser shields and redirect the plasma power to the engine room", the Captain said to the nice gay asian guy at the helm.
    "Aye-aye, Captain!"
    "Chechov set course for 11am, and Uhuru get me volume on the phone."
    "Aye-aye, Captain!"

    "Drop the phaser shields, Captain?"
    "Yes Spock, my gut instincts tell me that Klingon shorts are too busy on the shores of Valeant to notice our manouvers on the Enterprise"
    "Gut instincts Captain?", replied Spock
    "%#@*ing Vulcan!", shouted the angry Doctor Bones.
    Everybody laughs, even Spock.

    Sentiment: Strong Buy

  • Reply to

    Is Arena on Gilead's Radar for an Acquisition?

    by dalesurf318 Mar 21, 2016 10:30 AM
    sauve9 sauve9 Mar 22, 2016 10:09 AM Flag

    "What Gilead Will Pay For Arena Pharmaceuticals"

    Sentiment: Strong Buy

  • Encouraging price/volume
    early here, always too early

    Sentiment: Strong Buy

1.62+0.03(+1.89%)May 26 4:00 PMEDT